The biopharmaceutical firm said the offering would raise up to $86.25 million, although the company has not revealed how many shares it is planning to sell in the offering.
New Jersey-based Aegerion said it plans to use the proceeds from the IPO for repayment of debt and to fund the continued clinical development of cardiovascular drugs AEGR-733 and AEGR-427, as well as for general corporate purposes.
Lehman Brothers Inc., CIBC World Markets Corp, Thomas Weisel Partners LLC, CE Unterberg, Towbin LLC are listed as the underwriters.